Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VTV THERAPEUTICS INC.

(VTVT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VTv Therapeutics Sees Positive Results From Dose Study for Psoriasis Treatment

09/24/2021 | 06:37am EDT

By Chris Wack

vTv Therapeutics Inc. said it saw positive results from a multiple ascending dose study evaluating HPP737, an orally administered phosphodiesterase type 4 inhibitor for the treatment of psoriasis, in healthy adults.

The biopharmaceutical company said the trial enrolled 12 subjects in each of two dose cohorts, 15mg and 20mg, randomized to receive HPP737 or placebo orally once daily for 14 days.

Dose escalation up to 20mg/day demonstrated approximate dose proportional increases in exposure, while maintaining a favorable safety and tolerability profile with no dose limiting safety or tolerability findings observed. There were no serious adverse events and no discontinuations due to treatment emergent adverse events.

vTv said it believes that the current safety profile allows it to move forward in development with a drug that may achieve anti-inflammatory and anti-psoriatic responses without the significant safety issues of other PDE4 inhibitors.

With these results, vTv held a successful pre-IND meeting with the U.S. Food and Drug Administration Division of Dermatology and Dentistry. As a key outcome of the meeting, the company obtained acknowledgement that the completed studies appear reasonable to support the proposed dosing regimen of 20mg/day for 12 weeks.

The company also received feedback on the proposed safety monitoring and clinical trial endpoints. vTv plans to file an IND application later this year for a 12-week Phase 2 clinical trial evaluating the safety and efficacy of HPP737 in patients with moderate to severe psoriasis with study initiation targeted for early 2022.

vTv Therapeutics shares were up 31% to $2.32 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

09-24-21 0636ET

All news about VTV THERAPEUTICS INC.
10/12VTV THERAPEUTICS' : Diabetes Drug Trial Achieves Primary Endpoint
MT
10/12vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increa..
GL
10/12VTV THERAPEUTICS : Announces Positive Results from Mechanistic Study Indicating No Increas..
GL
10/12VTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increa..
CI
09/24Health Care Stocks Retreat Friday
MT
09/24Health Care Stocks Slip Pre-Bell Friday
MT
09/24VTV THERAPEUTICS : Health Care
MT
09/24Top Premarket Gainers
MT
09/24VTv Therapeutics Sees Positive Results From Dose Study for Psoriasis Treatment
DJ
09/24VTV THERAPEUTICS : Says Dose-Escalating Trial Shows Safety of Psoriasis Drug Candidate; Sh..
MT
More news
Financials (USD)
Sales 2021 3,00 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 88,5 M 88,5 M -
Capi. / Sales 2021 29,5x
Capi. / Sales 2022 88,5x
Nbr of Employees 25
Free-Float 28,2%
Chart VTV THERAPEUTICS INC.
Duration : Period :
vTv Therapeutics Inc. Technical Analysis Chart | VTVT | US9183851057 | MarketScreener
Technical analysis trends VTV THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,47 $
Average target price 6,75 $
Spread / Average Target 359%
Managers and Directors
Stephen L. Holcombe President & Chief Executive Officer
Rudy C. Howard EVP, Chief Financial & Accounting Officer
Robin E. Abrams Executive Chairman
Aaron H. Burstein Senior Vice President-Clinical Development
Carmen Valcarce Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
VTV THERAPEUTICS INC.-20.97%88
GILEAD SCIENCES, INC.16.08%84 795
BIONTECH SE203.83%59 820
WUXI APPTEC CO., LTD.29.45%57 897
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156